Title
Averting the legacy of kidney disease - focus on childhood

Permalink
https://escholarship.org/uc/item/76h370sd

Journal
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 49(5)

ISSN
0100-879X

Authors
Ingelfinger, JR
Kalantar-Zadeh, K
Schaefer, F
et al.

Publication Date
2016

DOI
10.1590/1414-431X20165314

License
CC BY 4.0

Peer reviewed
Averting the legacy of kidney disease - focus on childhood

J.R. Ingelfinger1,2, K. Kalantar-Zadeh3,4,5 and F. Schaefer6 on behalf of the World Kidney Day Steering Committee*

1Pediatric Nephrology Unit, MassGeneral Hospital for Children at Massachusetts General Hospital, Boston, MA, USA
2Department of Pediatrics, Harvard Medical School, Boston, MA, USA
3Division of Nephrology and Hypertension, Irvine School of Medicine, University of California, Irvine CA, USA
4VA Long Beach Healthcare System, Long Beach, CA, USA
5Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA
6Division of Pediatric Nephrology, Center for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany

Abstract

World Kidney Day 2016 focuses on kidney disease in childhood and the antecedents of adult kidney disease that can begin in earliest childhood. Chronic kidney disease (CKD) in childhood differs from that in adults, in that the largest diagnostic group among children includes congenital anomalies and inherited disorders, with glomerulopathies and kidney disease as a consequence of diabetes being relatively uncommon. In addition, many children with acute kidney injury will ultimately develop sequelae that may lead to hypertension and CKD in later childhood or in adult life. Children born early or who are small-for-date newborns have relatively increased risk for the development of CKD later in life. Persons with a high-risk birth and early childhood history should be watched closely in order to help detect early signs of kidney disease in time to provide effective prevention or treatment. Successful therapy is feasible for advanced CKD in childhood; there is evidence that children fare better than adults, if they receive kidney replacement therapy including dialysis and transplantation, although only a minority of children may require this ultimate intervention. Because there are disparities in access to care, effort is needed so that children with kidney disease, wherever they live, may be treated effectively, irrespective of their geographic or economic circumstances. Our hope is that the World Kidney Day will inform the general public, policy makers and caregivers about the needs and possibilities surrounding kidney disease in childhood.

Introduction

“For in every adult there dwells the child that was, and in every child there lies the adult that will be.”
John Connolly, The Book of Lost Things

The 11th World Kidney Day will be celebrated on March 10, 2016, around the globe. This annual event, sponsored jointly by the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), has become a highly successful effort to inform the general public and policy makers about the importance and ramifications of kidney disease. In 2016, World Kidney Day will be dedicated to kidney disease in childhood and the antecedents of adult kidney disease, which can begin in earliest childhood.

Children who endure acute kidney injury (AKI) from a wide variety of conditions may have long-term sequelae that can lead to chronic kidney disease (CKD) many years later (1–4). Further, CKD in childhood, much of it congenital, and complications from the many non-renal diseases that can affect the kidneys secondarily, not only lead to substantial morbidity and mortality during childhood but also result in medical issues beyond childhood (Figure 1). Indeed, childhood deaths from a long list of communicable diseases are inextricably linked to kidney involvement. For example, children who succumb to cholera and other diarrheal infections often die not from the infection but because of AKI induced by volume depletion and shock. In addition, a substantial body of data indicates that hypertension, proteinuria and CKD in adulthood have childhood antecedents—from as early as in utero and perinatal life (see Table 1 for definitions of childhood). World Kidney Day 2016 aims to heighten general awareness that much of adult renal disease is actually initiated in childhood. The understanding of high risk diagnoses and events that occur in childhood...
have the potential to help professionals to identify and intervene preemptively in people at higher risk for CKD during their lifetimes.

Worldwide epidemiological data on the spectrum of both CKD and AKI in children are currently limited, though increasing in scope. The prevalence of CKD in childhood is rare, and has been variously reported at 15–74.7 per million children (3). Such variation is likely because data on CKD are influenced by regional and cultural factors, as well as by the methodology used. The World Health Organization (WHO) has recently added kidney and urologic disease to mortality information tracked worldwide, which should be a valuable source of such data over time, although yet WHO does not post the information by age group (5). Databases such as the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) (6), the U.S. Renal Data System (USRDS) (7), and the European Dialysis and Transplant Association (EDTA) registry (8) include data on pediatric end-stage renal disease (ESRD), and on CKD. Projects such as the ItalKid (9) and Chronic Kidney Disease in Children (CKiD) (10) studies, the Global Burden of Disease Study 2013, as well as registries that now exist in many countries provide important information, although more is required (11).

AKI may lead to CKD, according to selected adult population studies (12). The incidence of AKI among children admitted to an intensive care unit varies widely from 8 to 89% (1). The outcome depends on the available resources. The results from projects such as the AWARE study, a five-nation study of AKI in children, are awaited (13). Single-center studies, as well as meta-analyses indicate that both AKI and CKD in children account for a minority of CKD worldwide (2,3). However, it is increasingly evident that kidney disease in adulthood often springs from a childhood legacy.

### Spectrum of pediatric kidney diseases

The conditions that account for CKD in childhood, with a predominance of congenital and hereditary disorders, differ substantially from those in adults. To date, mutations in more than 150 genes have been found to alter kidney development or specific glomerular or tubular functions (14). Most of these genetic disorders present during childhood, and many lead to progressive CKD. Congenital anomalies of the kidney and urinary tract (CAKUT) account for the largest category of CKD in children (see Table 2) and include renal hypoplasia/dysplasia and obstructive uropathy (2). Important subgroups among renal dysplasias are the cystic kidney diseases, which originate from genetic defects of the tubulop epithelial cells’ primary cilia. Many pediatric glomerulopathies are caused by genetic or acquired defects of the podocytes, the unique

<table>
<thead>
<tr>
<th>Life stage</th>
<th>WHO definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perinatal period</td>
<td>22 completed weeks of gestation to day 7 of postnatal life</td>
</tr>
<tr>
<td>Neonatal period</td>
<td>Birth to Day 28 of postnatal life</td>
</tr>
<tr>
<td>Infancy</td>
<td>Birth to 1 year of age</td>
</tr>
<tr>
<td>Childhood</td>
<td>1 year of age to 10 years of age</td>
</tr>
<tr>
<td>Adolescence</td>
<td>10 years of age to 19 years of age</td>
</tr>
</tbody>
</table>

Data in this table are as defined by the World Health Organization (WHO) (5). There is worldwide variation in how these stages are defined. Some would define "young people" as those aged 24 or less. In the United States, childhood is, as a whole, defined as younger than age 21.
cell type lining the glomerular capillaries. Less common but important causes of childhood CKD are inherited metabolic disorders such as hyperoxaluria and cystinosis, and atypical hemolytic uremic syndrome (a thrombotic microangiopathy related to genetic abnormalities of the complement, coagulation or metabolic pathways) (2).

In various classifications, there are no clear guidelines on how to categorize children who have suffered AKI and apparently recovered, or how and whether to include children who have had perinatal challenges, likely resulting in a relatively low nephron number.

Among children with childhood-onset of ESRD, glomerulopathies are slightly more common and congenital anomalies less common (Table 2), due to the typically more rapid nephron loss in glomerular disease. However, recent evidence suggests that many patients with milder forms of CAKUT may progress to ESRD during adulthood, peaking in the fourth decade of life (15).

There are national and regional differences in the types and course of both AKI and CKD during childhood and beyond. Death from kidney disease is higher in developing nations (3), and national and regional disparities in care and outcome must be addressed. Further, access to care is variable, depending on the region, the country, and its infrastructure. By focusing on kidney disease in childhood, cost-effective solutions may be reached, as treating disease early and preemptively may prevent later, more advanced CKD. Outcomes depend on the availability of care and management. Treating children, even from infancy, who have AKI and CKD that require renal replacement therapy (RRT) can be effective in mitigating the burden of kidney disease in adulthood. Doing so requires resources that focus on the most expeditious and cost-effective ways to deliver acute RRT in childhood.

### Table 2. Etiology of chronic kidney disease in children*

<table>
<thead>
<tr>
<th>Etiology</th>
<th>CKD (% range)</th>
<th>ESRD (% range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAKUT</td>
<td>48–59%</td>
<td>34–43%</td>
</tr>
<tr>
<td>GN</td>
<td>5–14%</td>
<td>15–29%</td>
</tr>
<tr>
<td>HN</td>
<td>10–19%</td>
<td>12–22%</td>
</tr>
<tr>
<td>HUS</td>
<td>2–6%</td>
<td>2–6%</td>
</tr>
<tr>
<td>Cystic</td>
<td>5–9%</td>
<td>6–12%</td>
</tr>
<tr>
<td>Ischemic</td>
<td>2–4%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Rare causes of chronic kidney disease (CKD) include congenital nephrotic syndrome, metabolic diseases, and cystinosis. Miscellaneous causes depend on how such entities are classified. CAKUT: congenital anomalies of the kidney and urinary tract; GN: glomerulonephritis; HN: hereditary nephropathy; HUS: hemolytic uremic syndrome. *From Hambalt et al. (2). CKD data are from NAPRTCS, the Italian Registry and the Belgian Registry. End-stage renal disease (ESRD) data are from ANZDATA, ESPN/ERA-EDTA, UK Renal Registry and the Japanese Registry.

---

### Congenital kidney disease and the implications of perinatal programming

In regions where antenatal fetal ultrasounds are routine, many children with urologic abnormalities are identified antenatally, which permits early intervention. However, in much of the world, children with structural abnormalities are not identified until much later, when symptoms develop. While generalized screening for proteinuria, hematuria and urinary tract infections are carried out in some countries and regions, there is a lack of consensus as to its effectiveness. However, there is a general agreement that children with antenatal ultrasound examinations that indicate possible genitourinary anomalies, children with a family history of kidney disease, and children with signs such as failure to thrive or a history of urinary tract infection, voiding dysfunction or an abnormal appearing urine should be examined (2). Initial screening would include a focused physical examination and a urine dipstick, formal urinalysis and a basic chemistry panel, followed by a more specialized evaluation, if indicated.

Depending on the diagnosis, definitive therapy may be indicated. However, the evidence that therapy will slow progression of CKD in childhood remains limited. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antioxidants and possibly dietary changes may be indicated, depending on the diagnosis. However, dietary changes need to permit adequate growth and development. The ESCAPE trial provided evidence that strict blood pressure control retards progression of CKD in children, irrespective of the type of underlying kidney disease (16).

Some children may require RRT in early infancy. Recent data pooled from registries worldwide indicate good survival, even when dialysis is required from neonatal age (2,17). Kidney transplantation, the preferred RRT for children, is generally suitable after 12 months of age, with excellent patient and allograft survival, growth, and development.

Evidence is accumulating that childhood-onset CKD leads to accelerated cardiovascular morbidity and shortened life expectancy (2). Ongoing large prospective studies, such as the Cardiovascular Comorbidity in Children with CKD (4C) Study, are expected to inform about the causes and consequences of early cardiovascular disease in children with CKD (18).

In addition to children with congenital kidney disease, it is now known that other perinatal events may affect future health of children with absence of evident kidney disease in early life (19). Premature infants appear to be particularly at risk for kidney disease long after they are born, based both on observational cohort studies, as well as on case reports (19,20). Increasingly premature infants survive, including many born well before nephrogenesis is complete (20). The limited data available indicate that, during neonatal intensive care unit treatment, such babies receive many nephrotoxins, and that those dying prior to...
discharge from the nursery have fewer and larger glo-
menuli (21). Additionally, those surviving have evidence of
renal impairment that may be subtle (22). Even more con-
cerning, abundant epidemiological data indicate that persons
born at term but with relatively low birth weights may be
at high risk for hypertension, albuminuria and CKD in later life
(23). When specific measurements are pursued, such per-
sons, as adults, may have fewer nephrons, thus a low
cardiorenal endowment.

In focusing on children for World Kidney Day, we
would note that it is key to follow kidney function and blood
pressure throughout life in those persons born early or
small-for-dates. By doing so, and avoiding nephrotoxic
medications throughout life, it may be possible to avert
CKD in many people.

**Resources and therapeutics for children –
differences from therapeutics in adults**

Disparities exist in the availability of resources to treat
AKI in children and young people. Consequently, too
many children and young adults in developing nations
succumb if AKI occurs. To address the problem the
International Society of Nephrology has initiated the
Saving Young Lives Project, which aims both to prevent
AKI with prompt treatment of infection and/or delivery of
appropriate fluid and electrolyte therapy, and to treat AKI
when it occurs. This ongoing project in Sub-saharan Africa
and South East Asia, in which four kidney foundations
participate equally (International Pediatric Nephrology
Association (IPNA), ISN, International Society for Perito-
neal Dialysis (ISPD), and Sustainable Kidney Care
Foundation (SKCF)), focuses on establishing and main-
taining centers for the care of AKI, including the provision
of acute peritoneal dialysis. It links with the ISN’s 0 by
25 project, which calls on members to ensure by 2025 that
nobody dies from preventable and acute kidney injury.

In view of the preponderance of congenital and
hereditary disorders, therapeutic resources for children
with CKD have historically been limited to a few immuno-
logical conditions. Very recently, progress in drug develop-
ment in concert with advances in genetic knowledge and
diagnostic capabilities has begun to overcome the
long-standing ‘therapeutic nihilism’ in pediatric kidney
disease. Atypical hemolytic uremic syndrome, long con-
sidered ominous, with a high likelihood of progression to
ESRD and post-transplantation recurrence, has turned
into a treatable condition with the advent of a monoclonal
antibody that specifically blocks C5 activation (24).
Another example is the use of vasopressin receptor
antagonists to retard cyst growth and preserve kidney
function in polycystic kidney disease (25). First proven
 efficacious in adults with autosomal dominant polycystic
kidney disease, therapy with vaptans holds promise also
for the recessive form of the disease, which presents as,
and often progresses to, ESRD during childhood.

However, patient benefit from pharmacological research
breakthroughs is jeopardized on a global scale by the
enormous cost of some of the new therapeutic agents. The
quest for affordable innovative therapies for rare diseases
will be a key issue in pediatric nephrology in the years to
come.

The identification of children likely to benefit from
novel therapeutic approaches will be greatly facilitated by
the development of clinical registries that inform about
the natural disease course, including genotype-phenotype
correlations. Apart from disease-specific databases, there
is also a need for treatment-specific registries. These are
particularly relevant in areas where clinical trials are
difficult to perform due to small patient numbers and lack
of industry interest. Treatment-specific registries are
also important for therapies in need of global develop-
ment or improvement. For instance, there is currently a
large international gradient in the penetration and
performance of pediatric dialysis and transplantation.
While pediatric treatment and patient survival rates are
excellent and even superior to those of adults in many
industrialized countries, it is estimated that chronic RRT
is not offered at all to almost half of the world’s childhood
population. Providing access to RRT for all children will
be a tremendous future challenge. To obtain reliable
information on the demographics and outcomes of
pediatric RRT, the IPNA is about to launch a global
population-based registry. If successful, the IPNA RRT
registry might become a role model for global data
collection.

**Transition from pediatric to adult care**

Transition of care for adolescents with kidney disease
into an adult setting is critical both for patients and their
caregivers. Non-adherence is a too-frequent hallmark of
transition from pediatric to adult care for young patients
with chronic disease states (26–28). Hence, considered
steps combined with systematically defined procedures
supported by validated pathways and credible guidelines
must be in place to ensure successful outcomes.

In the process of change from pediatric to adult care,
“transition”, which should occur gradually, must be
distinguished from “transfer”, which is often an abrupt
and mechanistic change in provider setting. Introducing
the concept of transition should be preemptive, starting
months or years prior to the targeted time, as children
move into adolescence and adulthood. The ultimate goal
is to foster a strong relationship and individualized plan in
the new setting that allows the patient to feel comfortable
enough to report non-adherence and other lapses in care.

A transition plan must recognize that the emotional
maturity of children with kidney disease may differ widely.
Assessment of the caregiver and the family structure as
well as cultural, social, and financial factors at the time of
transition is the key, including a realistic assessment of
caregiver burden (4). The appropriate timing and format of transition may vary widely among different patients and in different settings; therefore, a flexible process without a set date and even without a delineated format may be preferred.

Importantly, transition may need to be slowed, paused or even reversed temporarily during crises such as disease flares or progression, or if family or societal instability occurs. A recent joint consensus statement by the ISN and the IPNA proposed steps consistent with the points just outlined, aiming to enhance the transition of care in kidney disease in clinical practice (29,30).

**Call for generating further information and action**

Given vulnerabilities of children with kidney disease, including impact on growth and development and future life as an adult, and given the much greater proportion of children in developing nations facing resource constraints, educating everyone involved is imperative in order to realign communications and actions (31,32). These efforts should foster regional and international collaborations and exchange of ideas between local kidney foundations, professional societies, other not-for-profit organizations, and states and governments, so as to help empower all stakeholders to improve the health, well-being and quality of life of children with kidney diseases and to ensure their longevity into adulthood.

**References**


34. Gulland A. WHO agrees to set up body to act on non-communicable diseases. *BMJ* 2010; 341: c7086, doi: 10.1136/bmj.c7086.
